tbuckley/cabot-search huggingface dataset:
Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials
Authors: Zobair M. Younossi, Maria Stepanova, Patrick Marcellin, Nezam Afdhal, Kris V. Kowdley, Stefan Zeuzem, Sharon L. Hunt
Journal: Hepatology (2015)

Treatment with interferon (IFN) and ribavirin (RBV) significantly impairs quality of life and other patient‐reported outcomes (PROs). Patient experience with IFN‐ and RBV‐free anti‐HCV (hepatitis C virus) regimens has not been reported. We assessed PROs in patients treated with ledipasvir and sofosbuvir (LDV/SOF) with and without RBV. Four different PRO questionnaires were administered at baseline, during, and post‐treatment in HCV genotype 1 patients treated with LDV/SOF±RBV (ION‐1, ‐2, and ‐3). A total of 1,952 patients were enrolled to be treated for 8 (N = 431), 12 (N = 867), or 24 weeks (N = 654) with LDV/SOF (N = 1,080) or LDV/SOF+RBV (N = 872). Baseline demographics and psychiatric disorders were similar between treatment groups (all P &gt; 0.05). Patients receiving LDV/SOF regimens showed significant improvement of PRO scores during treatment (up to +7.4%, +7.0%, and +6.7% on a normalized 0%‐100% scale in the 8‐, 12‐, and 24‐week‐long treatment groups, respectively (all P &lt; 0.0001). These PRO improvements coincided with early viral suppression after 2 weeks of treatment and maximized by the end of treatment. On the other hand, during treatment with LDV/SOF+RBV, PRO scores declined (up to −5.5% regardless of treatment duration; P &lt; 0.0001). Receiving RBV was an independent predictor of PRO impairment in multivariate analysis (beta up to −5.9%; P &lt; 0.0001). Patients who achieved sustained virological response at 12 weeks showed significant improvement of their PROs post‐treatment (up to +8.3%; P &lt; 0.0001). Conclusion : IFN‐ and RBV‐free regimens with LDV/SOF result in early HCV suppression with simultaneous improvement in PROs that continued throughout the duration of treatment and post‐treatment. (H epatology 2015;61:1798‐1808)
Pioneer Medicine—Dr. Joseph O'Dwyer and Dr. Wm. Dunlop
Authors: J. W. Crane
Journal: Annals of Internal Medicine (1930)

Article1 February 1930Pioneer Medicine—Dr. Joseph O'Dwyer and Dr. Wm. DunlopJ. W. CRANEJ. W. CRANESearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-3-8-856 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOne of the fascinations in studying pioneer life is the discovery in unexpected places of some reminder of the doctor who had in his day contributed abundantly to the health and happiness of his community. The chicken coop may be a storehouse for such finds (Fig. 1.) A pair of saddle bags brought to Ontario from the New England States by a United Empire Loyalist doctor was found covered with hay in the manger of an unused barn.The University of Western Ontario was most fortunate in securing Dr. Joseph O'Dwyer's surgical bag containing several types of intubation tubes, some...References LIZARSMACFARLANE RK: In the Days of Canada Company, Toronto, 1896. Google Scholar CANNIFF W: The Medical Profession in Upper Canada, pp. 352-362, Toronto, 1894. Google Scholar DUNLOP A: Dunlop of that Ilk, pp. 46-62, 1898. Google Scholar MACLISE : Gallery of Illustrious Literary Men. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Western Ontario Medical School London, Ontario*Read before the American College of Physicians, Annual Clinical Week, April 12, 1929, Boston. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1930Volume 3, Issue 8Page: 856-862KeywordsHappinessIntubation ePublished: 1 December 2008 Issue Published: 1 February 1930 PDF downloadLoading ...
Diversion and Abuse of Methadone Prescribed for Pain Management
Authors: Theodore J. Cicero, James A. Inciardi
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Budesonide in Preschool-Age Children with Recurrent Wheezing
Authors: Alison Poulton, Anthony Liu, Ralph Nanan
Journal: New England Journal of Medicine (2012)

To the Editor: In the Maintenance and Intermittent Inhaled Corticosteroids in Wheezing Toddlers (MIST) trial (ClinicalTrials.gov number, NCT00675584), Zeiger et al. (Nov. 24 issue)1 suggest that intermittent high-dose budesonide was equal in efficacy to daily low-dose budesonide in preschool-age children with recurrent wheezing. This conclusion requires some further clarification. The study involved children with episodic, mild, and moderate asthma. Children with more severe asthma, with either more than six courses of oral glucocorticoids or more than two hospitalizations for wheezing during the previous year, were excluded. Mild episodic asthma constitutes the vast majority of cases and, at least in Australia, these children are not routinely prescribed preventive inhaled lowdose glucocorticoids.2 These children, by definition, are asymptomatic for most of the time and would have little scope for improvement on treatment. Can the authors please clarify what proportion of their study cohort had episodic asthma? Alison Poulton, M.D. Anthony Liu, M.P.H., M.Med.Ed. Ralph Nanan, Dr.Med., Habil. University of Sydney Sydney, NSW, Australia alison.poulton@sydney.edu.au No potential conflict of interest relevant to this letter was reported.
Book: Rosalind Franklin: The Dark Lady of DNA
Authors: J. A. Rosenfeld
Journal: BMJ (2003)

Brenda Maddox Harper Collins, £20, pp 400 ISBN 0 00257149 8 Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img> Rosalind Franklin, the biophysicist whose work provided the scientific support for Watson and Crick's development of the structure of DNA, has remained a mystery, her opinions and motivations hidden. Was she—as described by her colleague Maurice Wilkins, who shared the Nobel prize with Watson and Crick—the “dark lady,” a bellicose spinster who could not collaborate and resented their work and originality? Was her work ignored because it was insignificant or because she was antisocial? Or was she a brilliant scientist and feminist, a sacrificial victim, her work overlooked and her progress diminished because she was an outsider who didn't fit into the “old boy” network? The truth, of course, lies … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif
Long-Term Follow-Up After Deferral of Percutaneous Transluminal Coronary Angioplasty of Intermediate Stenosis on the Basis of Coronary Pressure Measurement 11This study was supported in part by Grant 95001 from the “Stichting Vrienden van het Hart” (Friends of the Heart Foundation), Eindhoven, The Netherlands.
Authors: G.Jan Willem Bech, Bernard De Bruyne, Hans J.R.M. Bonnier, Jozef Bartunek, William Wijns, Kathinka Peels, Guy R. Heyndrickx, Jacques J. Koolen, Nico H.J. Pijls
Journal: Journal of the American College of Cardiology (1998)
Charles George Drake David Ferguson Stanley Ferguson Basil Herbert ("Bunny") Goodrich Thomas Adesanya Ige Grillo Ursula Hickman Malik Laki Kassam Colin Henry Rylands Knowles Colin William Morley William Wallace Park Nigel David Bentley Preston Karel Styblo
Authors: J. Walton, T. Ganner, F. Mead, G. Ferguson, J R Sudbury, A. Lucas, R. Vella, J Forbes, S Russell, M Martin, J Steyn, M. Nicholls, J. Hopewell, A. Ranken, I. Brown, S. Fan, H. B Goodall, A J Hicks, J. F Broekmans
Journal: BMJ (1998)

FRCSCan), died from lung cancer on
Neonatal Signs After In Utero Exposure to Selective Serotonin Reuptake Inhibitors—Reply
Authors: Eydie L. Moses-Kolko, Debra Bogen, James Perel, Katherine L. Wisner, Amy Bregar, Kathleen Uhl, Bob Levin
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 848: Galectin-1 mediates radiation-related lymphopenia in non-small cell lung cancer and attenuates tumor radiation response
Authors: Peiwen Kuo, Scott Bratman, David Shultz, Rie von Eyben, Cato Chan, Ziwei Wang, Carmen Say, Aparna Gupta, Bill W. Loo, Amato Giaccia, Albert Koong, Maximilian Diehn, Quynh-Thu Le
Journal: Cancer Research (2014)

Abstract Decreased circulating lymphocytes after tumor irradiation has been linked to worse outcomes in several cancers treated with fractionated radiotherapy. The mechanism underlying radiation (RT)-induced lymphopenia is not well understood. Here, we show that lymphopenia also occurs after stereotactic ablative radiotherapy for early stage non-small cell lung cancer, and that it is associated with reduced survival. We provide evidence that RT-induced secretion of Galectin-1 (Gal-1), a b-galactoside binding protein, can potentially explain for this phenomenon. Using matched Gal-1 wild type and null mice together with Lewis lung carcinoma cells stably knocked-down of Gal-1 or scramble control, we show that irradiation of Gal-1 expressing tumor increases Gal-1 secretion in the blood and that it is linked to decreased circulating T-lymphocytes. This was ablated by either genetic down regulation of Gal-1 in the tumor or inhibition of Gal-1 activity by TDG. Moreover, Gal-1 down regulation resulted in enhanced radiation sensitivity in vitro as well as less intratumoral T cell apoptosis and angiogenesis in vivo, resulting in marked tumor growth delay and reduced spontaneous lung metastases when combined with radiotherapy. Similar results were noted when Gal-1 function was inhibited with TDG in vivo. Together, our data identify Gal-1 as an important mediator of RT-related lymphopenia and its proangiogenic and T cell proapototic effect may explain for the poorer outcome associated with RT-related lymphopenia. Gal-1 is therefore a new potential therapeutic target to combine with radiotherapy. Citation Format: Peiwen Kuo, Scott Bratman, David Shultz, Rie von Eyben, Cato Chan, Ziwei Wang, Carmen Say, Aparna Gupta, Bill W. Loo, Amato Giaccia, Albert Koong, Maximilian Diehn, Quynh-Thu Le. Galectin-1 mediates radiation-related lymphopenia in non-small cell lung cancer and attenuates tumor radiation response. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 848. doi:10.1158/1538-7445.AM2014-848
The New Editor
Authors: Truman G. Schnabel
Journal: Annals of Internal Medicine (1971)

Editorials1 June 1971The New EditorTRUMAN G. SCHNABEL JR., M.D.TRUMAN G. SCHNABEL JR., M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-74-6-1002 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOn 1 July 1971 Dr. Edward J. Huth will become the fifth editor of the ANNALS OF INTERNAL MEDICINE*. The Board of Regents, in appointing Dr. Huth as Dr. Elkinton's successor, believes that the College has been most fortunate in finding an outstanding physician and scholar to be the new Editor of the ANNALS.Dr. Huth began his editorial duties with the ANNALSin October of 1960, when as Assistant Editor he joined Dr. Elkinton in opening the editorial office in Philadelphia after its move from Baltimore. He was appointed Associate Editor in 1963 and has filled that post full... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: American College of Physicians Philadelphia, Pa.*The ANNALS OF INTERNAL MEDICINE is the successor of Annals of Clinical Medicine published in Volumes 1 to 5, July 1922 to June 1927; Dr. Frank Smithies served as its Supervising Editor through June 1924, when he was followed by Dr. Alfred S. Warthin as Editor. Volume 1 of the ANNALS OF INTERNAL MEDICINE was published in the second half of 1927 and first half of 1928. Dr. Warthin served as Editor of the ANNALS until 1931. He was followed by Dr. Carl V. Weller, 1931 to 1933, Dr. Maurice C. Pincoffs, 1933 to 1960, and Dr. J. Russell Elkinton, 1960 to 1971. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1971Volume 74, Issue 6Page: 1002-1002 Issue Published: 1 June 1971 PDF downloadLoading ...
Effect of partial ablation of the bone marrow and of splenectomy on the hepatic lesions produced by 2-acetylaminofluorene.
Authors: J. Stasney, K. E. Paschkis, A. Cantarow
Journal: Cancer Research (1950)

Large portions (about 30–40 per cent) of the accessible bone marrow of rats were destroyed and replaced by inert material; in some experiments, this procedure was combined with splenectomy. One group of animals received AAF in its diet. Control groups included AAF-treated intact rats and rats not receiving the carcinogen but subjected to bone-marrow ablation with and without splenectomy.

After ablation, these animals exhibited leukocytosis and slight extramedullary hematopoiesis, but no leukemia. Exposure of this vigorously regenerating hematopoietic system to AAF failed to induce leukemia. The significance of these findings in regard to the relation of intensified “normal” cell proliferation to carcinogenesis is discussed briefly.

Cancer of the liver, induced by feeding AAF, appeared earlier and grew more extensively in male rats subjected to bone-marrow ablation, or to the latter combined with splenectomy, than in intact animals receiving the carcinogen. Female rats, whose livers are less susceptible to the carcinogenic action of AAF, failed to exhibit intensification of liver cancer under the conditions of the experiment.
Abstract OT2-4-02: Testing BRCA 1/2 mutation using next generation sequencing (BRCANGS)
Authors: Hyung Seok Park, Seo Jin Park, Sanghwa Kim, Jegyu Ryu, Jee Ye Kim, Seho Park, Seung Il Kim, Joo Hyuk Sohn, Jong Rak Choi
Journal: Cancer Research (2015)

Abstract Testing BRCA 1/2 mutation is important for patients with breast cancer, and Sanger sequencing is a standard method to identify BRCA 1/2 mutation. Next generation sequencing (NGS) is a high-throughput parallel sequencing that can provide genetic information with high accuracy. NGS is a faster and cost-effective method to detect gene mutations compared to Sanger sequencing. This study is a prospective non-randomized obsevational study which evaluates the clinical role of NGS testing for BRCA 1/2 compared to Sanger sequencing. Eligibility criteria are wome aged 19 to 80 years, patients with breast or ovarian cancer history in 2nd degree family members, male breast cancer, bilateral breast cancer, patient with breast cancer under 40 year of age, simultaneous breast and ovarian cancer, patients with epithelial ovarian cancer, and breast cancer with other simultaneous extramammary malignancy. Primary endopont of the study is the overall accuracy of NGS compared to Sanger sequencing. Seconary endponts are sensitivity, specifcity, false negative, and false positive rates of NGS compared to Sanger method. Target accrual of the pilot study is 12 patients, and futher extension of patients accrual is scheduled after the anlaysis of the pilot study. This study is approved by institutial review board of Severance Hospital. The study is conducted and planned by Prof. HS Park, Yonsei University College of Medicine, Seoul, Korea and supported by Korea Breast Cancer Foundation. ClinicalTrials.gov identifier is NCT02151747. Citation Format: Hyung Seok Park, Seo Jin Park, Sanghwa Kim, Jegyu Ryu, Jee Ye Kim, Seho Park, Seung Il Kim, Joo Hyuk Sohn, Jong Rak Choi. Testing BRCA 1/2 mutation using next generation sequencing (BRCANGS) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr OT2-4-02.
Evidence based paediatrics: Evidence based management of nocturnal enuresis
Authors: J. H C Evans
Journal: BMJ (2001)

This is the fourth in a series of five articles 

A 10 year old boy has been brought to see you because of bedwetting. He is dry during the day. The only treatment he has had ever is desmopressin once when he was away at a camp for two nights. He was dry both nights but he slept very little, and his parents are not sure whether the desmopressin was responsible for his dry nights. Normally he is wet most nights. His parents realise that the wetting is now beginning to upset the boy and both he and they are requesting help. Nothing of note is found on examination and on urine culture.

#### Summary points

Daytime urinary symptoms in a bedwetting child suggest an underlying bladder dysfunction rather than nocturnal enuresis

Enuresis alarms are effective and safe treatment but require several months of continuous use and are therefore unsuitable for some families

Desmopressin and imipramine both improve bedwetting but there is no good evidence of lasting benefit after treatment is stopped

Imipramine has high frequency of serious adverse effects and should be used with great caution

The parents and child should actively participate in the choice of treatment

Bedwetting is a common symptom with many causes.1 Nocturnal enuresis is the most frequent cause; it is recognised by the absence of other urinary symptoms or signs of disease. Most children presenting with nocturnal enuresis have never been reliably dry, but in a minority enuresis has started after they had become dry, possibly triggered by stressful life events. If daytime wetting is present the child is most likely to have the urge syndrome, with or without urge incontinence as well, or dysfunctional voiding—functional bladder disturbances that result in incontinence. Rarely, incontinence may be due to structural abnormalities of the urinary tract, such as …
Abstract #LB-216: Effects of vandetanib on lung adenocarcinoma cells harboring an EGFR T790M mutation in vivo
Authors: Eiki Ichihara, Kadoaki Ohashi, Nagio Takigawa, Masahiro Osawa, Hiromasa Takeda, Nobuaki Ochi, Daijiro Harada, Masayuki Yasugi, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Cancer Research (2009)

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Vandetanib is a tyrosine kinase inhibitor (TKI) with activity against vascular endothelial growth factor receptor 2 (VEGFR-2), epidermal growth factor receptor (EGFR) and REarranged during Transfection (RET) receptor signaling, which has recently completed phase III trials in the second-line setting of advanced non-small cell lung cancer as monotherapy and in combination with docetaxel or pemetrexed. The mechanisms of acquired resistance to vandetanib remain unclear, so we established in vitro vandetanib-resistant PC-9/VanR cells from PC-9, a vandetanib-sensitive lung adenocarcinoma cell line harboring an EGFR exon 19 deletion (E746-A750) mutation, by chronic exposure to this agent. PC-9/VanR cells were 50-fold more resistant to vandetanib than PC-9 cells in vitro and showed emergence of the EGFR T790M mutation (AACR 2008, Abstract #678). Compared with PC-9 cells, PC-9/VanR cells showed modest MET amplification (1.5-fold) and similar VEGFR-2 inhibition by vandetanib. Of note, in PC-9/VanR cells, phosphorylated MET was suppressed by an irreversible EGFR-TKI, suggesting that MET activity in PC-9/VanR cells is dependent on EGFR signaling, and that MET signaling is not the primary mechanism of resistance to vandetanib. In vivo , vandetanib inhibited the growth of PC-9/VanR tumor xenografts model through anti-angiogenic effects mediated by VEGFR-2 inhibition. Vandetanib exhibited similar antitumor efficacy against two additional established human lung adenocarcinoma tumor cell xenografts harboring EGFR T790M mutations (H1975, RPC-9). In contrast, gefitinib showed less in vivo activity against xenografts harboring an EGFR T790M mutation. These data provide a strong scientific rationale for investigating vandetanib in clinical settings where acquired resistance through emergence of EGFR T790M mutations limits the effectiveness of gefitinib.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-216.